Research programme: ultra fast-acting insulin aspart - Albireo Pharma/HEC PharmAlternative Names: Insulin aspart 30 - Albireo Pharma/HEC Pharm; Ultra-rapid-acting insulin aspart - Albireo Pharma/HEC
Latest Information Update: 12 Jan 2017
At a glance
- Originator Biodel
- Developer Albireo Pharma
- Class Insulins; Peptides
- Mechanism of Action Insulin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 22 Apr 2014 Early research in Diabetes mellitus in USA (Parenteral)